Major depressive disorder (MDD)

This study is an extension of an earlier trial, testing the safety and tolerability of SPT-300 in 360 adults with major depressive disorder, with or without anxious distress. Participants who completed the prior study will receive SPT-300 for 6 weeks. The goal is to monitor side …

This study tests whether adding ketamine tablets to a new antidepressant can reduce depression symptoms faster in adults with major depression. Twelve participants will take four doses of ketamine over one week while starting a standard antidepressant. The goal is to see if sympt…

This study looks at whether giving vitamin D supplements to women with depression and low vitamin D levels can change their brain waves. Researchers will measure brain activity using a non-invasive EEG scan before and after supplementation. The trial includes 34 women aged 20-40 …

This pilot study tests whether a wearable device that delivers intermittent white light at 60 Hz can safely help people with moderate to severe depression. Thirty adults on stable antidepressant medication will wear the goggles for 30 minutes daily over two weeks. The main goal i…

This study tests whether a 12-week physical activity program can reduce depressive symptoms in adults with major depressive disorder. 110 participants are split into two groups: one continues antidepressant treatment alone, the other adds a tailored exercise routine. Researchers …

Researchers are sequencing the gut microbiomes of people with a wide range of conditions, from autism and Alzheimer's to Crohn's disease and multiple sclerosis, to see whether bacterial patterns differ by disease. The study also enrolls healthy participants for comparison. By mat…

This study compares a new selegiline skin patch to an existing one (EMSAM®) to see how well the skin tolerates it. Researchers will apply both patches to 230 healthy adults and check for irritation or allergic reactions. The goal is to ensure the new patch is safe for the skin be…

This study looks at how older adults with major depression handle emotions and make choices compared to healthy adults. Researchers will use brain scans and computer tasks to measure emotional recognition, reward processing, and impulsivity. The goal is to better understand the b…

This study looks at whether adding aripiprazole to the antidepressant escitalopram can reduce pathological rumination—repetitive, intrusive negative thoughts—in people with major depressive disorder. 108 participants will receive either escitalopram alone or escitalopram plus ari…

This study looks at how things like social support, income, and health habits are linked to mental health and brain diseases such as depression, Alzheimer's, and Parkinson's. Researchers will collect surveys, blood samples, and optional brain scans from over 1,300 adults in Europ…

This study is analyzing blood samples from 1,799 people with Alzheimer's, dementia, depression, bipolar disorder, schizophrenia, or Parkinson's disease. Researchers want to see if certain substances in the blood can help doctors diagnose and manage these conditions more accuratel…

This study looks at whether a hormone called oxytocin, measured in saliva during a psychedelic therapy session, can help predict how well people with major depression respond to treatment. Researchers will track changes in depression symptoms, flexibility in thinking, and anxiety…

This study uses brain scans and magnetic stimulation to compare brain activity in 160 adults with autism, depression, both, or neither. Researchers want to understand how brain inflammation and the balance of excitation and inhibition relate to social and emotional symptoms. No t…

This study looks at brain tissue and lab-grown nerve cells from people with schizophrenia, depression, bipolar disorder, frontotemporal dementia, and Alzheimer's. Researchers want to find out how problems with synapses—the connections between brain cells—differ in these condition…

This study looks back at 376 patients who received psychedelic-assisted therapy with LSD or psilocybin for depression, anxiety, PTSD, or substance use disorders. Researchers want to see if the intensity of the psychedelic experience is linked to better outcomes. All data comes fr…